Results: MHE Question of the Week About Copay Accumulators
The results of this week’s poll about whether copay accumulators should be banned.
The results are in, and 60% of readers think copay accumulators should be banned.
So far, 20 states have moved to ban copay accumulators.
Health insurers and PBMs in favor of the ban say that copay accumulators counteract copay insurance programs. Patient groups say accumulator programs make important drugs more expensive and cause harm because people can’t afford their medications after the copay assistance support runs out and they have to pay full price till the deductible is met
We want to know what you’re thinking! Every Monday morning, the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. We collect your answer and post the results on Friday.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Cigna Reveals Multi-Year Plan to Simplify Healthcare, Boost Transparency and Improve Patient Support
February 3rd 2025This follows the company’s recent earnings call, where executives discussed the organization’s growth and future plans, highlighting its focus on serving the best interests of their consumers.
Read More
The HIV Epidemic in Trump’s America
February 3rd 2025Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Read More
